| Name | N-(1,3-dihydroxyoctadec-4-en-2-yl)hexadecanamide |
|---|---|
| Synonyms |
16:0 CERAMIDE
D-ERYTHRO-SPHINGOSINE, N-PALMITOYL N-Hexadecanoyl-D-sphingosine N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-htadecenyl]-Hexadecanamide C16 Ceramide (N-Palmitoylsphingosine, D-erythro) N-PALMITOYL-D-ERYTHRO-SPHINGOSINE SYNTHETICAL C16 Ceramide (Palmitoyl ceramide), Endogenous ceramide Hexadecanamide, N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-htadecen-1-yl] Cer(d18:1/16:0)/N-(hexadecanoyl)-sphing-4-enine C16 Ceramide (d18:1/16:0) N-((2S,3R,E)-1,3-Dihydroxyoctadec-4-en-2-yl)palmitamide N-PALMITOYL-D-ERYTHRO-SPHINGOSINE N-[(1S,2R,3E)-2-Hydroxy-1-(hydroxyMethyl)-3-htadecen-1-yl]-hexadecanaMide N-Palmitoyl-D-sphingosine semisynthetic from bovine brain D-sphingosine N-[(2S,3S)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanamide N-HEXADECANOYL-D-ERYTHRO-SPHINGOSINE C16 CERAMIDE N-PALMITOYL-D-SPHINGOSINE N-PalMitoyl-D-erythro-sphingosine, synthetical, ( E.E.) N-Palmitoyl-D-erythro-sphingosineCeramide C16 N-Palmitoyl-D-sphingosine C16-D-ERYTHRO-CERAMIDE PALMITOYL CERAMIDE CERAMIDE-C16 C16 Ceramide, Ceramide NS C16 ceramide, N-Hexadecanoyl-D-sphingosine, N-Palmitoyl-D-erythro-sphingosine, Palmitoyl ceramide N-(hexadecanoyl)-sphing-4-enine N-PALMITOYLSPHINGOSINE, D-ERYTHRO N-Palmitoylsphingosine N-HEXADECANOYL-D-SPHINGOSINE N-Palmitoyl- D -sphingosine Palmitoyl ceramide N-Palmitoyl-D-erythro-sphingosine, N-Hexadecanoyl-D-erythro-sphingosine, Palmitoyl ceramide N-PALMITOYL-D-ERYTHRO-SPHINGOSINE;C16 CERAMIDE (D18:1/16:0) N-Palmitoyl-D-erythro-sphingosine C16-ceramide (2S,3R,4E)-2-N-PalMitoyloctadecasphinga-4-ene (2S,3R,4E)-2-(Palmitoylamino)-4-octadecene-1,3-diol N-PALMITOYL CERAMIDE |
| Description | C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding[1]. |
|---|---|
| Related Catalog | |
| Target |
Human Endogenous Metabolite |
| In Vitro | C16-Ceramide interacts with p53 within its core domain. p53 forms complex with natural C16-Ceramide in the cell[1]. C16-Ceramide (2.5-50 μM; 0-48 h) strongly decreased HCT116 cell viability in a time- and concentration-dependent manner[2]. C16-Ceramide (12 μM; 48 h) induces apoptosis through Btf (Bcl-2-associated transcription factor) in HCT116 cells[2]. C16-ceramide (12 μM; 0-6 h) and Btf expression up-regulate p53 and BAX expression. C16-ceramide down-regulates Mdm2 expression via Btf[2]. Cell Viability Assay[2] Cell Line: HCT116 cells Concentration: 2.5, 5, 10, 12, 20, 50 µM Incubation Time: 0-48 h Result: Strongly decreased cell viability in a time- and concentration-dependent manner. Western Blot Analysis[2] Cell Line: HCT116 cells Concentration: 12 μM Incubation Time: 1, 3 and 6 h Result: Increased PARP cleavage, decreased pro-caspase 3. Decreased the levels of stratifin and stathmin, increased the expression of prohibitin and Btf. RNAi-mediated Btf depletion alsopartially inhibited BAX expression after the treatment. Significantly decreased luciferase activity and Mdm2 protein expression levels. |
| Density | 0.919g/cm3 |
|---|---|
| Boiling Point | 675.396ºC at 760 mmHg |
| Melting Point | 94-95ºC |
| Molecular Formula | C34H67NO3 |
| Molecular Weight | 537.90100 |
| Flash Point | 362.267ºC |
| Exact Mass | 537.51200 |
| PSA | 69.56000 |
| LogP | 9.95390 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.48 |
| Storage condition | −20°C |
| Water Solubility | Soluble in DMF at 0.15mg/ml |